The DRD2 polymorphism — principally the Taq I A1 allele of the dopamine D2 receptor gene — occupies a pivotal position in the depth-psychology corpus as the molecular anchor for reward deficiency syndrome (RDS) and its behavioral sequelae. Kenneth Blum and collaborators constitute the dominant voice, marshalling neurogenetic evidence that an abnormality at the DRD2 locus reduces the density of dopamine receptor sites in mesolimbic reward circuitry, generating a constitutional predisposition toward addictive, compulsive, and impulsive behavior. The corpus tracks the Taq I D2A1 allele across a remarkably broad phenotypic terrain — alcoholism, pathological gambling, smoking, ADHD, Tourette syndrome, and binge eating — establishing a recurrent motif of dopaminergic insufficiency. A secondary thread, drawn from Comings and colleagues and reported by Blum, elaborates the heterosis phenomenon at the DRD2 locus, wherein heterozygotes exhibit more extreme behavioral scores than either homozygote class, complicating simple allelic dosage models. The Lanius volume introduces gene-environment interaction as a corrective frame, situating genetic vulnerability within developmental and epigenetic contexts. Notably, the corpus is sparse on critical appraisals of DRD2 association methodology; it leans heavily toward translational and therapeutic implications, positioning the polymorphism as a diagnostic biomarker amenable to nutraceutical and neuroadaptagen intervention.